Geode Capital Management LLC Cuts Stake in DaVita Inc. $DVA

Geode Capital Management LLC reduced its stake in shares of DaVita Inc. (NYSE:DVA) by 4.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 978,790 shares of the company’s stock after selling 44,584 shares during the quarter. Geode Capital Management LLC owned about 1.39% of DaVita worth $111,016,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently bought and sold shares of DVA. Elevation Wealth Partners LLC grew its stake in shares of DaVita by 147.3% during the fourth quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock worth $31,000 after acquiring an additional 165 shares during the last quarter. Canada Pension Plan Investment Board acquired a new position in shares of DaVita during the 2nd quarter worth approximately $43,000. iSAM Funds UK Ltd purchased a new stake in shares of DaVita during the third quarter worth approximately $46,000. Stance Capital LLC purchased a new stake in DaVita in the 3rd quarter valued at $47,000. Finally, Camelot Portfolios LLC purchased a new stake in DaVita in the 4th quarter valued at $57,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

DVA has been the topic of several research reports. Deutsche Bank Aktiengesellschaft raised DaVita from a “hold” rating to a “buy” rating and increased their target price for the stock from $126.00 to $220.00 in a research note on Wednesday, May 6th. Truist Financial raised their target price on DaVita from $158.00 to $205.00 and gave the stock a “hold” rating in a research report on Friday, May 8th. TD Cowen raised their target price on DaVita from $144.00 to $201.00 and gave the stock a “hold” rating in a research report on Monday, May 11th. Zacks Research raised DaVita from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Finally, UBS Group lifted their price target on DaVita from $190.00 to $235.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $199.17.

Insider Transactions at DaVita

In other DaVita news, CFO Joel Ackerman sold 51,471 shares of the stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the completion of the transaction, the chief financial officer directly owned 132,434 shares of the company’s stock, valued at approximately $25,440,571.40. This trade represents a 27.99% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 1.50% of the company’s stock.

DaVita Trading Up 0.1%

Shares of NYSE DVA opened at $192.28 on Friday. The company has a market cap of $12.34 billion, a price-to-earnings ratio of 17.84, a price-to-earnings-growth ratio of 0.63 and a beta of 0.91. DaVita Inc. has a 12-month low of $101.00 and a 12-month high of $202.69. The stock’s 50 day simple moving average is $171.47 and its 200 day simple moving average is $143.18.

DaVita (NYSE:DVA) last posted its earnings results on Tuesday, May 5th. The company reported $2.87 EPS for the quarter, beating the consensus estimate of $2.33 by $0.54. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The firm had revenue of $3.42 billion for the quarter, compared to analysts’ expectations of $3.36 billion. During the same period last year, the firm earned $2.00 EPS. The firm’s revenue was up 6.0% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, equities analysts forecast that DaVita Inc. will post 15.07 earnings per share for the current fiscal year.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.